
Jones offered his insights for discharging patients as well as follow-up outpatient treatment.
Jones is an infectious diseases clinical pharmacy specialist at St Joseph’s/Candler Health System, practicing in the Savannah City-Wide Antimicrobial Management Program. He also serves as an clinical adjunct associate professor at the University of Georgia College of Pharmacy.

Jones offered his insights for discharging patients as well as follow-up outpatient treatment.

In this conversation, Jones discussed looking at the benefits around choosing 1 specific therapy for treatment.

Bruce Jones, PharmD, FIDSA, BCPS offered clinical considerations for the concerns around infective endocarditis and when choosing empiric therapy.

Bruce Jones, PharmD, FIDSA, BCPS provided insights on challenging patients with comorbidities such as type 2 diabetes and higher BMI.

In the last segment of the series, Jones offered his insights for when he considers discharging patients.

In this conversation, Jones discussed concerns around empirical antimicrobial treatment and opportunities to narrow down therapies.

Bruce Jones, PharmD, FIDSA, BCPS offered clinical considerations for patient dosing and clinical management strategies associated with concurrent therapy.

Bruce Jones, PharmD, FIDSA, BCPS provides commentary on treating challenging patients with comorbidities such as type 2 diabetes, higher BMI, and advanced age.

Patients with a penicillin allergy can be safely delabeled using minimal resources, opening up treatment options.

Panelists hypothesize on theoretical downsides of resistance development for gram-negative infections and reflect on the importance of implementing outpatient parenteral antibiotic therapy.

Published: November 25th 2024 | Updated:

Published: December 6th 2024 | Updated:

Published: June 13th 2024 | Updated:

Published: June 20th 2024 | Updated:

Published: November 18th 2024 | Updated:

Published: September 18th 2018 | Updated: